Who Supplies Pemetrexed to India from ITALY

To import finished pharmaceutical formulations containing Pemetrexed into India, the following regulatory approvals are mandatory:

1. 1Import License: Obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).
2. 2Drug Import License: Secure a license from the Central Drugs Standard Control Organisation (CDSCO) for importing drugs.
3. 3Product Registration: Register the specific Pemetrexed formulation with CDSCO, providing detailed product information.
4. 4Certificate of Pharmaceutical Product (CoPP): Provide a CoPP from the manufacturing country, confirming the product's market authorization.
5. 5No Objection Certificate (NOC): If the product is already marketed in India, an NOC from the existing marketer may be required.

The registration process typically takes 6–12 months, depending on the completeness of the application and regulatory reviews.

Imported Pemetrexed formulations must undergo quality testing to ensure compliance with Indian standards:

1. 1Batch Testing: Each batch must be tested in a CDSCO-approved laboratory for quality, purity, and potency.
2. 2Certificate of Analysis (CoA): A CoA from the manufacturer, detailing the product's specifications and testing results, is required.
3. 3Stability Data: Provide stability data demonstrating the product's shelf-life under Indian climatic conditions, adhering to ICH guidelines for Zone IV.
4. 4Pharmacopoeia Compliance: Ensure the product meets the standards set by the Indian Pharmacopoeia.

Customs drug inspectors may conduct port inspections to verify compliance with these requirements.

As of April 2026, there have been no significant changes in India's import policies affecting finished pharmaceutical formulations containing Pemetrexed. The Production Linked Incentive (PLI) scheme primarily targets domestic manufacturing and does not directly impact imports of finished formulations. Bilateral agreements between India and Italy have not introduced preferential treatment for such imports.

India imports finished Pemetrexed formulations to meet the demand for patented and branded anticancer treatments not available domestically. Specific dosage forms, such as injections, may not be produced locally due to technological constraints. The Indian market for Pemetrexed formulations is substantial, with total imports valued at $28.8 million across 138 exporters to 92 countries. Italy's contribution to this market is significant, indicating a strong demand for Italian formulations.

The import duty structure for Pemetrexed formulations under HS Code 30049049 is as follows:

• Basic Customs Duty (BCD): 10%
• Social Welfare Surcharge (SWS): 10% of BCD, totaling 1%
• Integrated Goods and Services Tax (IGST): Applicable as per prevailing rates

There are no additional duties such as Anti-Dumping Duty or National Calamity Contingent Duty (NCCD) applicable to this product. Exemptions or preferential rates for Italy origin under HS Code 30049049 are not specified.

Italy's pharmaceutical industry is renowned for high-quality standards and advanced manufacturing capabilities. Italian manufacturers offer Pemetrexed formulations that may include specialized dosage forms or formulations not produced domestically in India. While other countries like China, Germany, and the United States also supply Pemetrexed formulations, Italy's reputation for quality and innovation provides a competitive edge in the Indian market.

India imports Pemetrexed formulations from Italy due to the availability of patented formulations and specialized dosage forms not produced domestically. Italian manufacturers offer high-quality products that meet international standards, which are essential for treating specific types of cancer. The advanced technology and manufacturing capabilities in Italy enable the production of formulations that may not be feasible to produce locally in India.

When compared to other sources like China, Germany, and the United States, Italy offers a competitive advantage in terms of product quality and innovation. Italian pharmaceutical products are known for their adherence to stringent quality standards and regulatory compliance. While other countries may offer lower prices, Italy's reputation for quality and reliability makes it a preferred choice for importing Pemetrexed formulations into India.

Potential risks for Indian importers include:

• Single-Source Risk: Dependence on a single supplier can lead to supply disruptions.
• Currency Risk: Fluctuations in the Euro–INR exchange rate can affect costs.
• Regulatory Changes: Changes in import regulations or tariffs can impact the supply chain.
• Quality Incidents: Issues with product quality can lead to regulatory scrutiny and market withdrawal.
• Shipping Disruptions: Delays due to port congestion or logistical challenges can affect delivery timelines.

Historically, there have been no significant shortages reported in the supply of Pemetrexed formulations from Italy to India.

To mitigate risks and ensure a reliable supply chain, Indian buyers should consider:

1. 1Dual-Sourcing: Engage multiple suppliers to reduce dependency on a single source.
2. 2Inventory Planning: Maintain adequate stock levels to buffer against supply chain disruptions.
3. 3Payment Terms: Negotiate favorable terms such as Letters of Credit (LC) to manage financial risks.
4. 4Supplier Qualification: Conduct thorough due diligence to ensure supplier reliability and product quality